Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BSD Medical approvals

This article was originally published in The Gray Sheet

Executive Summary

Firm will submit PMA in 2004 for BSD-2000 deep cancer hyperthermia treatment system currently undergoing IDE clinicals for treatment of multiple cancers, including those in the pelvic region. Upgraded versions of the firm's BSD-500 systems received approval Oct. 10 to supplement an initial PMA approval for superficial and interstitial treatment of near-surface cancers. Priced at $175,000-$250,000, the new models' touch-screen displays allows better control and operation, according to the firm. BSD primarily will market the BSD-500 as a complement to installed interstitial brachytherapy systems...

You may also be interested in...



BSD Medical stock listing

BSD-2000 deep cancer hyperthermia treatment system manufacturer's application for listing on the American Stock Exchange earns approval, Salt Lake City, Utah firm states May 3 (1"The Gray Sheet" Oct. 20, 2003, In Brief). BSD, which currently trades on the OTC Bulletin Board under the symbol "BSDM," expects to begin trading on the exchange in "next several days"...

Teva Plans To Appeal EU Provigil Fine

Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).

Coronavirus Update: SK Bioscience, Biological E, DongWha And Celltrion Report Progress

SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel